- 1 May 2023Portfolio NewsAstellas Pharma buys Iveric Bio for $5.9 billion
- 27 April 2023Portfolio NewsTherini Bio Raises $36M Series A Financing to Develop Fibrin-Targeted Therapies for Neurodegenerative and Retinal Diseases
- 18 April 2023Portfolio NewsNitrase Therapeutics Presents Preclinical Data on the Role of Enzymatic Nitration in Oncology at the American Association for Cancer Research Annual Meeting
- 6 April 2023Portfolio NewsQurAlis Announces First Patient Dosed With QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS
- 28 March 2023Portfolio NewsBicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates
- 28 March 2023Portfolio NewsPrilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD Clinical Study for Huntington’s Disease
- 9 March 2023Portfolio NewsALS biotech QurAlis gets $88M boost from four pharmas for pair of PhI studies
- 9 March 2023Portfolio NewsQurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases
- 6 March 2023Portfolio NewsEyeBio Announces First Asset in Innovative Pipeline of Retinal Disease Treatments and Appoints Industry Leaders to Executive Team
- 23 February 2023Portfolio NewsAviadoBio Signs Exclusive License Agreement with Neurgain Technologies for Novel Gene Therapy Spinal Delivery Technology
- 23 February 2023Portfolio NewsPrilenia Announces Topline Results for Pridopidine in Phase 2 ALS Study
- 20 February 2023SV NewsImpact funds help fight dementia and antibiotic resistance